JRSBRT 10.3, p. 219-223 (PDF)

After payment has been processed for your order of a digital copy (PDF) of this article, you will see a download link on your completed order page and also receive an email containing a download link. The links, which will enable you to download one copy of the article, will expire after 24 hours.

Stereotactic body radiation therapy for intrathoracic oligometastases from endometrial and ovarian cancers: A single institution experience
Anirudh Bommireddy, Cole Billena, Sudha Amarnath and Sheen Cherian

Background: Stereotactic body radiation therapy (SBRT) is well established for oligometastatic gynecologic malignancies, commonly using 24 Gy in 3 fractions for abdominopelvic lesions. However, outcomes for intrathoracic lesions treated with this regimen are limited. We report institutional outcomes using SBRT 24 Gy in 3 fractions for intrathoracic oligometastases from endometrial and ovarian cancers.

Methods: Patients with oligometastatic endometrial and ovarian malignancies and intrathoracic lesions treated with SBRT (24 Gy in 3 fractions) between 2019 and 2024 were retrospectively reviewed. The primary endpoint was local control (LC). Secondary endpoints included PET response, tumor marker response, overall survival (OS), and toxicity.

Results: The study included 8 patients with 12 lesions, with a median follow-up of 14 months (range: 1–68). Primary sites were ovarian (75%) and endometrial (25%). There was 1 local failure, yielding a 2 year LC of 86%. All evaluable lesions demonstrated PET response, with 86% complete resolution. Tumor markers normalized in all elevated cases. The 2 year OS was 69%. There were no grade ≥2 toxicities.

Conclusions: SBRT 24 Gy in 3 fractions for intrathoracic oligometastases from endometrial and ovarian malignancies appears safe and effective, providing excellent local control with minimal toxicity.

Keywords: stereotactic body radiation therapy, SBRT, lung metastases, gynecologic malignancy